Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice.

AIMS: The aim of this study was to investigate the angiographic and intravascular ultrasound (IVUS) findings of the Endeavor zotarolimus-eluting stent (ZES) in patients from a "real-world" clinical practice. METHODS AND RESULTS: From January to March 2006, 100 patients undergoing routine or emergency percutaneous intervention were prospectively enrolled at one institution. Overall, 39% of the patients were diabetics and 80.8% of lesions were type B2/C. A total of 140 lesions were successfully treated with 174 ZES, and procedural success was 98%. Mean vessel diameter was 2.69 mm and mean lesion length was 16.0 mm; at 6-month angiographic follow-up (completed in 96%), in-stent late lumen loss was 0.66 mm, and in-segment restenosis was 8.2%. Angiographic restenosis was increased among diabetics (15.5 vs. 2.6%, p=0.009), and diabetes was the only significant predictor of angiographic restenosis (OR=15.27 [95%CI 2.45-95.04], p=0.003). By IVUS (performed in 88% at 6-month), % volume obstruction was 14.4+/-13.4%, and there was no late acquired incomplete stent apposition (ISA). At 1-year, overall MACE rate was 6%, including 5 TLRs (4% of patients), with no occurrence of stent thrombosis. CONCLUSIONS: In this prospective "real-world" experience, the ZES demonstrated favourable angiographic and IVUS results in complex patients, with overall in-stent late lumen loss of 0.66 mm, and absence of late acquired ISA. At 1-year, there were no safety concerns including absence of death and stent thrombosis.

Hiperplasia neo-intimal intra-stent e progressão de placa aterosclerótica no vaso-alvo em pacientes tratados com stents libertadores de zotarolimus / Intra-stent neointimal hyperplasia and plaque progression inthe target vessel in patients treated with zotarolimus eluting stents

Fundamentos: Após intervenções coronárias percutâneas, tem sido descrita uma reação inflamatória local que está diretamente relacionada à hiperplasia neo-intimal e à reestenose. O quanto esse processo inflamatório pode levar à progressão de placa aterosclerótica no vaso tratado ou nas outras artérias coronárias é ainda motivo de debate. Objetivo: Avaliar se há relação entre o grau de hiperplasia intimal intra-stent e a progressão de placa no vaso tratado. Método: Estudo retrospectivo com 36 pacientes com 40 lesões tratados com stents liberadores de zotarolimus, avaliados com ultra-sonografia intracoronária (USIC) após o procedimento e no reestudo protocolar tardio. Obtidos o porcentual do volume de obstrução intimal intra-stent (%VO) e a mudança de volume da placa aterosclerótica fora do segmento tratado (ΔVAT). Avaliamos a intensidade da relação entre as variáveis %VO e ΔVAT por meio do coeficiente de correlação de Spearman. Resultados: O %VO foi de 14,5% ± 14,9%. Observada progressão de placa nas porções proximais (20,04 mm³/mm ± 58,61 mm³/mm) e distais (7,37 mm³/mm ± 25,86 mm³/mm) ao segmento tratadocom stent. Não houve correlação entre o porcentual de hiperplasia neo-intimal e o grau de progressão de placa proximal (-0,015; p = 0,93), distal (-0,166; p = 0,36) ou em ambos os segmentos (-0,026; p = 0,89). Conclusão: Neste grupo de pacientes tratados com stents liberadores de zotarolimus, a ausência de correlação entre o volume de obstrução intimal intra-stent e a progressão de placa fora do segmento tratado sugere a existência de diferentes mecanismos inflamatórios por trás desses processos.

Background: A local inflammatory response has been described after percutaneous coronary intervention and has been associated with neointimal hyperplasia and restenosis. Whether this inflammatory process might cause atherosclerotic progression in the same coronary artery or in the other coronary arteries is a matter of debate. Objectives: To assess a possible relation between the degree of neointimal hyperplasia and the progression of atherosclerotic plaque in the nearby stented segments. Methods: Retrospective study in which 36 patients with 40 lesions treated with zotarolimus eluting stents were studied with intravascular ultrasound (IVUS) during the index and follow-up procedures. In-stent percent volume obstruction (%VO) and change in atheroma volume in the arterial subsegments outside the stented segment (ΔATV) were obtained. We assessed the strength of the relationship between %VO and ΔATV by the Spearman correlation coefficient. Results: %VO was 14.5% ± 14.9%. Plaque progression was observed in proximal (20.04 mm³/mm ± 58.61 mm³/mm) and distal (7.37 mm³/mm ± 25.86 mm³/mm) arterial subsegments nearby the stented segment. There was no correlation between the degree of neointimal hyperplasia and the degree of plaque progression either in the proximal (-0.015; p = 0.93), distal (-0.166; p = 0.36) or both segments (-0.026, p = 0.89). Conclusion: In this group of patients treated with zotarolimus eluting stents, the lack of correlation between the degree of neointimal hyperplasia and plaque progression suggests different inflammatory reactions behind those phenomena.